News

Business Wire8mon
Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI
SOMERVILLE, Mass.--(BUSINESS WIRE)--Generate:Biomedicines (“Generate”) today announced a multi-target collaboration with Novartis (NYSE: NVS) to discover and develop protein therapeutics ...
Business Wire2y
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning ...
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs), today announced a global, multi-target license and option ...